Gene therapy for primary immunodeficiencies: Part 2

► Clinical trials for CGD and WAS showed proof of principle of gene therapy. ► Gammaretroviral vectors are associated with insertional mutagenesis. ► Lentiviral vectors have improved safety and are more potent in transducing stem cells. ► A strong rationale supports gene therapy for other primary immunodeficiencies.